News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
227,918 Results
Type
Article (7162)
Company Profile (16)
Press Release (220740)
Multimedia
Podcasts (3)
Webinars (1)
Section
Business (63128)
Career Advice (294)
Deals (14768)
Drug Delivery (28)
Drug Development (36790)
Employer Resources (24)
FDA (6412)
Job Trends (4908)
News (121807)
Policy (11628)
Tag
2024 BioMidwest Digital (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (1)
2024 Lone Star Bio Digital (1)
Academia (567)
Accelerated approval (2)
Adcomms (7)
Allergies (35)
Alliances (14770)
ALS (28)
Alzheimer's disease (600)
Antibody-drug conjugate (ADC) (40)
Approvals (6458)
Artificial intelligence (102)
Autoimmune disease (10)
Automation (3)
Bankruptcy (147)
Best Places to Work (4608)
BIOSECURE Act (2)
Biosimilars (21)
Biotechnology (18)
Bladder cancer (49)
Brain cancer (14)
Breast cancer (106)
Cancer (1133)
Cardiovascular disease (70)
Career advice (258)
Career pathing (4)
CAR-T (89)
Cell therapy (215)
Cervical cancer (12)
Clinical research (31180)
Collaboration (303)
Compensation (89)
Complete response letters (7)
COVID-19 (722)
CRISPR (18)
C-suite (75)
Cystic fibrosis (37)
Data (1278)
Denatured (1)
Depression (19)
Diabetes (109)
Diagnostics (2228)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (48)
Drug pricing (41)
Drug shortages (17)
Duchenne muscular dystrophy (40)
Earnings (33299)
Editorial (13)
Employer branding (1)
Employer resources (19)
Events (31013)
Executive appointments (247)
FDA (7077)
Featured Employer (3)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (268)
Gene editing (46)
Generative AI (10)
Gene therapy (127)
GLP-1 (184)
Government (1253)
Grass and pollen (2)
Guidances (35)
Healthcare (6139)
Huntington's disease (5)
IgA nephropathy (14)
Immunology and inflammation (36)
Indications (17)
Infectious disease (784)
Inflammatory bowel disease (59)
Inflation Reduction Act (5)
Influenza (24)
Intellectual property (51)
Interviews (45)
IPO (8030)
IRA (17)
Job creations (570)
Job search strategy (221)
Kidney cancer (8)
Labor market (5)
Layoffs (40)
Leadership (3)
Legal (2100)
Liver cancer (39)
Lung cancer (161)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (104)
MASH (37)
Medical device (4588)
Medtech (4589)
Mergers & acquisitions (7091)
Metabolic disorders (279)
Multiple sclerosis (38)
NASH (8)
Neurodegenerative disease (25)
Neuropsychiatric disorders (4)
Neuroscience (803)
NextGen: Class of 2025 (1506)
Non-profit (712)
Northern California (1265)
Obesity (138)
Opinion (75)
Ovarian cancer (53)
Pain (35)
Pancreatic cancer (46)
Parkinson's disease (66)
Partnered (5)
Patents (133)
Patient recruitment (61)
Peanut (17)
People (14523)
Pharmaceutical (8)
Pharmacy benefit managers (6)
Phase I (9952)
Phase II (13718)
Phase III (10288)
Pipeline (729)
Policy (33)
Postmarket research (796)
Preclinical (3629)
Press Release (9)
Prostate cancer (50)
Psychedelics (11)
Radiopharmaceuticals (118)
Rare diseases (156)
Real estate (1003)
Recruiting (7)
Regulatory (9145)
Reports (13)
Research institute (510)
Resumes & cover letters (39)
Rett syndrome (3)
RNA editing (2)
RSV (16)
Schizophrenia (26)
Series A (44)
Series B (30)
Service/supplier (2)
Sickle cell disease (23)
Southern California (1102)
Special edition (2)
Spinal muscular atrophy (31)
Sponsored (14)
Startups (674)
Stomach cancer (5)
Supply chain (25)
Tariffs (3)
The Weekly (1)
United States (10554)
Vaccines (167)
Venture capitalists (5)
Weight loss (76)
Women's health (6)
Worklife (4)
Date
Last 7 days (285)
Last 30 days (1051)
Last 365 days (15734)
2025 (4611)
2024 (16923)
2023 (19098)
2022 (22233)
2021 (23633)
2020 (21795)
2019 (14450)
2018 (10638)
2017 (11455)
2016 (9543)
2015 (11736)
2014 (8102)
2013 (5877)
2012 (6040)
2011 (6749)
2010 (6216)
Location
Africa (176)
Alabama (16)
Alaska (2)
Arizona (54)
Arkansas (3)
Asia (17549)
Australia (4848)
California (2858)
Canada (1116)
China (237)
Colorado (121)
Connecticut (161)
Delaware (58)
Europe (27965)
Florida (421)
Georgia (68)
Idaho (6)
Illinois (207)
India (20)
Indiana (123)
Japan (89)
Kansas (14)
Kentucky (5)
Louisiana (5)
Maine (36)
Maryland (350)
Massachusetts (2041)
Michigan (51)
Minnesota (102)
Missouri (36)
Montana (11)
Nebraska (8)
Nevada (39)
New Hampshire (36)
New Jersey (985)
New Mexico (3)
New York (907)
North Carolina (392)
North Dakota (2)
Northern California (1265)
Ohio (62)
Oklahoma (1)
Oregon (7)
Pennsylvania (672)
Puerto Rico (6)
Rhode Island (8)
South America (302)
South Carolina (11)
Southern California (1102)
Tennessee (42)
Texas (428)
Utah (68)
Virginia (76)
Washington D.C. (17)
Washington State (343)
West Virginia (2)
Wisconsin (11)
227,918 Results for "xstrahl limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Press Releases
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
April 14, 2025
·
5 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
Press Releases
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
April 7, 2025
·
4 min read
Press Releases
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
March 13, 2025
·
3 min read
Press Releases
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
December 5, 2024
·
19 min read
Press Releases
HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs
April 21, 2025
·
2 min read
Press Releases
Nemysis Limited Announces Collaboration With Avia Pharma AB as IHAT Distributor in Nordic Region
March 14, 2025
·
2 min read
Obesity
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
Despite comments made by a Novo Nordisk official this week, the company confirmed to
BioSpace
that it has no additional clinical trials of its GLP-1 drugs in addiction beyond a Phase II trial testing semaglutide and two other drugs with alcohol use as a secondary endpoint.
March 7, 2025
·
2 min read
·
Dan Samorodnitsky
Drug Development
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival compared to placebo for patients with limited-stage small cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy.
June 2, 2024
·
27 min read
1 of 22,792
Next
